内科学-心律失常-朱文青_第1页
内科学-心律失常-朱文青_第2页
内科学-心律失常-朱文青_第3页
内科学-心律失常-朱文青_第4页
内科学-心律失常-朱文青_第5页
已阅读5页,还剩94页未读 继续免费阅读

下载本文档

版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领

文档简介

Arrhythmia,Zhuwen-qing,Dep.OfCardiology,Zhong-ShanHospital,FuDanUniversity.Shanghai.China.,Conductionandanatomyofheart,Conductionsystem,StableSVTisgenerallywelltoleratedinpatientswithoutunderlyingheartdisease!?butmayleadtomyocardialischemiaorcongestiveheartfailureinpatientswithcoronarydisease,valvularabnormalities,andsystolicordiastolicmyocardialdysfunction.Ventriculartachycardia,iflasting1030secs,oftenresultsinhemodynamiccompromiseandismorelikelytodeteriorateintoventricularfibrillation.,RATEDifferentiationofSVTfromVA;Evaluationoftherapyinpatientswithaccessoryatrioventricularpathways;EvaluationoftheefficacyofpharmacotherapyinsurvivorsofsuddendeathorotherpatientswithsymptomaticorlifethreateningVT;Evaluationofpatientsforcatheterablationproceduresorantitachycardiadevices.,AutonomicTesting(TiltTableTesting)withrecurrentsyncopeornearSyncope,arrhythmiasarenocause.Thisisparticularlytruewhenthepatienthasnoevidenceofassociatedheartdiseasebyhistory,examination,ECG,ornoninvasivetesting.Syncopemaybeneurocardiogenicinorigin,mediatedbyexcessivevagalstimulationoranimbalancebetweensympatheticandparasympatheticautonomicactivity.,TECHNIQUESFOREVALUATINGRHYTHMDISTURBANCES,TECHNIQUESFOREVALUATINGRHYTHMDISTURBANCES,AutonomicTesting(TiltTableTesting),60-80,TECHNIQUESFOREVALUATINGRHYTHMDISTURBANCES,Antiarrhythmiadrug,Antiarrhythmicdrugshavelimitedefficacyandfrequentsideeffects.Theyareoftendividedintofourclasses.ClassIagentsblockmembranesodiumchannels.ThreesubclassesarefurtherdefinedbytheeffectofagentsonthePurkinjefiberactionpotentialClassladrugsslowtherateofriseoftheactionpotential(Vmax)andprolongitsduration,thusslowingconductionandincreasingrefractorineas.Classlbagentsshortenactionpotentialduration,theydonotaffectconductionorrefractoriness.ClassIcagentsprolongVmaxandslowrepolarization,thusslowingconductionandprolongingrefractoriness,butmoresothanclassladrugs,Antiarrhythmiadrug,ClassIIagents-beta-blockersDecreaseautomaticity,ProlongAVconduction,Prolongrefractoriness.,Antiarrhythmiadrug,ClassIIIagentsBlockpotassiumchannelsProlongrepolarization,wideningtheQRSandprolongingtheQTinterval.Decreaseautomaticityandconductionandprolongrefractoriness.,Antiarrhythmiadrug,ClassIVagents-slowcalciumchannelblockersDecreaseautomaticityandAtrioventricularconduction,Drugs,Antiarrhythmiadrug-Risk,TheriskofantiarrhythmicagentshasbeenhighlightedbytheCoronaryArrhythmiaSuppressionTrial(CAST).TwoclassIcagents(flecainide,encairfide)andaclamlaagent(moficizine)increasedmortalityratesinpatientswithasymptonlaticventricularectapyaftermyocardialinfarction.Therefore,theseagents(anyantiarrhythmicdrug)shouldnotbeusedexceptforlife-threateningventriculararrhythmiasandsymptomaticsupraventriculartachyarrhythmias.,RadiofrequencyAblation,AblationhasbecometheprimarymodalityoftherapyformanysymptomaticSVTIncludingAVNRTAVRT-involvingaccessorypathways,paroxysmalatrialtachycardia,inappropriatesinustachycardia,junctionaltachycardia,Manylaboratorieshaveachievedreasonablesuccessratesinpreventingatrialflutterwithrediofrequencytechniques,andexperiencewithatrialfibrillationisaccumlatingaswell.,RadiofrequencyAblation,CatheterablationofVAhasprovedmoredifficult.ThreespecilicformsofVAprovedtobeamenabletoradiofrequeneyablation.bundlebranchreentry,VToriginatinginrightventricuiaroutflowtract,VToriginatingintheleftsideoftheinterventricularseptum.OtherformsofVT,maybeamenabletoablation,butexperiencethusfarislimited.,RadiofrequencyAblation,Inaddition,someproceduresinvolvetransseptalorretrogradeleftventricularcatheterization,withtheattendantpotentialcomplicationsofaorticperforation,damagetotheheartvalves,orleft-sidedemboli.Theseproceduresaregenerallysafe,thoughthereisalowincidenceofperforationoftheatriaorrightventriclethatresultsinpericardialtamponadeandsufficientdamagetotheatriovantricularnodetorequirepermanentcardiacpacing.,AVRTablation,AVNRTAblation,Atrialtachycardia-ablation,Atrialfibrillationaccountsfor1/3ofallpatientdischargeswitharrhythmiaasprincipaldiagnosis.,2%VF,Datasource:BailyD.JAmCollCardiol.1992;19(3):41A.,34%AtrialFibrillation,18%Unspecified,6%PSVT,6%PVCs,4%AtrialFlutter,9%SSS,8%ConductionDisease,3%SCD,10%VT,SUPRAVENTRICULARARRHYTHMIASsinusbradycardia,CausesofSlowRhythms:HypoxiaHyperkalemiaAcuteMIHeartDiseaseIncreasedparasympathetictoneDrugeffectsfromnarcotics,benzodiazepines,digoxin,betablockers,propranolol,orcalciumchannelblockers,SinusBradycardia,DecreaseintherateofatrialdepolarizationRhythmisregularRate100beats/minPwave,PRinterval,andQRScomplexareallnormal,SinusTachycardia,Treatment:AlleviatetheunderlyingcauseinappropriatesinustachycardiathatmaybeverysymptomaticorleadtoLVcontractiledysfunction.Radiofrequeneymodificationofthesinusnodehasmitigatedthisproblem,ATRIALPREMATUREBEATS,APBoccurbeforethenextsinusnodeimpulseorareentry_circuitisestablished.Pwaveusuallydiffersfromthepatientsnormal.R-Rcyclelengthisusuallyunchangedoronlyslightlyprolonged.prematurebeatsoccurinnormalheartsandareneverasufficientbasisheartdisease.Speedingoftheheartratebyanymeansusuallyabolishesmostprematurebeats.EarlyAPBmaycauseaberrantQRScomplexesormaybenonconductedtotheventriclesbecausethelatterarestillrefractory.,VariabilityofVentricularEctopywithAge,Effectofageonprobability(%)ofhavingmorethanagivennumberofPVCsper24hoursinsubjectswithnormalhearts.,10-29,30-39,40-49,50-59,60-69,DatafromKostisJB.Circulation.1981;63(6):1353.,Age,VENTRICULARBEATS,DistinctioncanbeverydifficultinpatientswithawideQRS;itisimportantbecauseofthedifferingprognosticandtherapeuticimplicationsofeachtype.ventricularoriginincludeatrioventriculardissociation;aQRSdurationexceeding0.14s;captureorfusionbeats(infrequent);leftaxisdeviatinnwithrightbundlebranchblockmorphology;monophasic(R)orbiphasic(qR,QR.,orRS)complexesinV1,;and(6)aqRorQScomplexinV6.,VENTRICULARBEATS,SupraventricularoriginisfavoreclbyatriphasicQRScomplex,especiallyiftherewasinitialnegativityinleadsIandV6;ventricularratesexcceeding170/min;QRSdurationlongerthan0.12sbutnotlongerthan0.14s:thepresenceofpreexcitationsyndrome.,Asingleirritablefocuswithintheventriclefiresprematurelygivingrisetoanectopicbeat.QRSiswideIfeveryotherbeatisPVCventricularbigeminyIfeverythirdbeatisaPVCventriculartrigeminyIfeveryfourthbeatisPVCventricularquadrigeminyAPVCthatfallsontheTwaveprecipitatesVTorVF,VENTRICULARBEATS,VENTRICULARBEATS,Treatment:PVCswhichneedtobetreatedare:MultifocalOccurincoupletsFallonoraftertheTwaveThatoccurgreaterthan6perminute,PrematureVentricularContraction,TreatmentContinued:InthesettingofanacuteMI,PVCsneedtobeaggressivelytreatedwithnitroglycerine,aspirin,morphineandoxygen.LidocaineisthedrugofchoicetodiminishPVCs,butdoeslittletotheunderlyingpathology.,SUPRAVENTRICULARTACHYCARDIA,thecommonestparoxysmaltachycardiaandoftenoccursinpatientswithoutstructuralheartdisease.Attacksbeginandendabruptlyandmaylastafew,secondstoseveralhoursorlonger.Hrmaybe140-240/mia(usually160-220/min)andisperfectlyregular(despiteexerciseorchangeinposition).Pwaveusuallydiffersincontourfromshinsbeats.Asymptomatic,butsomeexperiencemildchestpainorshormessofbreath,especiallywhenepisodesareprolonged,evenintheabsenceofassociatedcardiacabnormalities.PSVTmayresultfromdigitalistoxicityandtheniscommonlyassociatedwithatrioventricularblock.,SVT,SVT,SVT-Care,AMechanicalMeasures:Avarietyofmethodshavebeenusedtointerruptattacks,andpatientsmaylearntoperformthesethemselves.TheseincludeValsalvasmaneuver,stretchingthearmsandbody,loweringtheheadbetweentheknees,coughing,andbreathholding.,SVT-treatment,B.DrugTherapy:Iffail,rapidlyintravenousagentswillterminatemorethan90%ofepisodes,Intravenousadenosine(orATP)hasaverybriefdurationofactionandminimalnegativeinotropieactivity,A6-mgbolusisadministered.Ifnoresponseisobservedafter10minutes,asecondandthird12-mgbolusshodldbegiven.Sincethehalf-lifeofadenosineislessthan10seconds,drugmustbegivenrapidly(in12secondsfromaperipheralintravenousline).Adenosineisverywelltolerated,butnearly20%-flushing,andsomepatientsexperienceseverechestdiscomfort.,SVTCare,CalciumchannelblockersalsorapidlyinduceatrioventricularblockandbreakmostepisodesofreentrySVT.IVverapamilmaybegivenasa2.5mg-bolus,followedbyadditionaldosesof2.5to5mgevery1-3minutesuptoatotalof20mgifbloodpressureandrhythmarestable.Iftherecurs,furtherdosescanbegiven,SVT-Care,Cardioversion:Ifthepatientishemodynamicallystableorifadenosineandvempamilarecontraindicatedorineffective,synchronizedelectricalcardioversion(beginningat100J)isalmostuniversallysuccessful.Ifdigitalistoxicityispresentorstronglysuspected,asinthecaseofparoxysmaltachycardiawithblock.electricalcardioversionshouldbeavoided.,PreventionofAttacks,A.RadiofrsquencyAblation:SafetyandLessrecurrentB.Drugs:Verapamil、Propafenone、Amiodarone,PreexcitationSyndromes,Wolff-ParkinsonWhitesyndrome.Directconnectionsbetweentheatriaandventricle(Kentbundles);Lown-Ganong-Levinesyndrome:shortPRintervalandnormalQRSmorphologyMahaimfibers:whollyorpartlywithinthenode,PreexcitationSyndromes,AVRT-WPW,Pathwaysoccurin0.1-0.3%.20-30%ofpatientswithtachyarrhythmiashaveatrialfibrillationorflutter!PatientswithRRintervalslessthan220msareathighestrisk.DigoxinSayNO!verapamilandbetablockersmaydecreaseAPrefractorinessandincreaseventricularresponseandshouldbeavoidedinatrialfibrillationwithaccessorypathwaysTreatment.,WPW,AVRTWPWCare,Radiofrequencycatheterablation;PharmacologicTherapy.,Atrialfibrillation,Atrialfibrillationisthecommonestchronicarrhythmia.Itoccursinrheumaticheartdisease,dilatedcardiomyopatliy,ASD,hypertension,mitralvalveprolapse,andhypertrophiccardiomyopathyaswellasinpatientswithnoapparentcardiacdisease.itmaybetheinitialpresentingsigninthyrotoxicosis.Atrialfibrillationoftenappearsparoxysmallybeforebecomingtheestablishedrhythm.,Atrialfibrillation,Atrialrateis350-600/min,butmostimpulsesareblockedattheatrioventricularnode.Diagnosis:ECG,Atrialfibrillation,Acutemanagementearlycardieversion-2448hsayNoOradequatelyanticoagulatedfor3-4weeksIVbeta-blockersorverapamilordiltiazem,digoxin,oracombinationoftheseapproaches.,Atrialfibrillation,TreatmentofChronicAtrialFibrillationTheproblemsposedbychronicAfareprimarilytwo:symptomsrelatedtothearrhythmiasandtheincreasedriskofthromhoemboliephenomena.Drug:anticoagulationorcontrolHrAblation:pacemakeretc.Surgeon,AtrialFlutter,AFislesscommonthanfibrillation.COPDorwithrheumaticorCHD,CHF,ASD,orsurgicallyrepairedcongenitalheartdisease.Atrialratesof250-350/rain,withtransmissionofevery2:1/3:1/4:1atrioventricularnodetotheventricles.,ATRIALFLUTTER,Chronicatrialflutterisoftenadifficultmanagementproblem,ratecontrolisdifficult.Drug:anticoagulationorcontrolHrAblation:pacemakeretc.Surgeon,ATRIALFLUTTER,DiagramofAtrialFlutterCircuitWithinRightAtrium,CosioFG.AmJCardiol.1993;71:705-709.,Inferiorvenacava-tricuspidvalveisthmus,ATRIALTACHYCARDIA,ThisisarhythmcharacterizedbyvaryingP-wavemorphology(bydefinition,threeororefoci)andmarkedlyirregularPPintervals.Therateisusuallybetween100and140/min,andatrieventricularblockisunusualMostpatientshavesevereassociatedCOPD.Treatmentoftheunderlyingconditionisthemosteffectiveapproach;verapamil,240-480mgdailyindivideddoses,isalsoofvalueinsamepatients.,ATRIALTACHYCARDIA,ATRIALTACHYCARDIA,ATRIOVENTRICULARTIONALRHYTHM,Theatrial-nodaljunctionorthenodal-Hisbundlejunctionsmayassumepacemakeractivityfortheheart,usuallyatarateof4060/min.Patientswithmyocarditis,CHD,anddigitalistoxicityaswellasinindividualswithnormalhearts.Diagnosis:ECG/monitoring,butitcanbesuspectedifIhejugularvenouspulseshowscannonawaves.NonparoxysmaljunctionaltachyeardiaresultsfromdigitalistoxicityorischemiaandisassociatedwithanarrowQRScomplexandarateusuallylessthan120-130/min.Consideredbenignwhenitoccursinacutemyocardialinfarction,buttheischemiamayalsocauseVTandVf.,VENTRICULARARRHYTHMIAS-ENTRICULARPREMATUREBEAT,VentricularPrematurebeatsarecharacterizedbywideQRScomplexesthatdifferinmorphologyfromthepatientsnormalbeats.TheyareusuallynotprecededbyaPwave,althoughretrogradeventriculoatrialConductionmayoccur.,VENTRICULARARRHYTHMIAS-VENTRICULARPREMATUREBEAT,VENTRICULARARRHYTHMIAS-VENTRICULARPREMATUREBEAT,Diagnosis:ECG/AmbulatorymonitoringTreatment:Drugs/AblationIfnoassociatedcardiacdiseaseispresentandasymptomatic,notherapyisindicated.mayexacerbateseriousarrhythmiasin520%ofpatients.Therefore,toavoidusingclassIorIIIantiarrhythmicagentsinpatientswithoutsymptoms.,VENTRICULARARRHYTHMIAS-VENTRICULARTACHYCARDIA,VTisdefinedasthreeormoreconsecutiveventricularprematurebeats.Theusualrateis160-140/mmandismoderatelyregularbutlesssothanatrialtachycardia.Diagnosis:ECG/Monitor/EPS,VENTRICULARARRHYTHMIAS-VT,VTcauseshypotension,heartfailure,ormyocardialischemia,synchronizedDCcardioversionwith100-360Jshouldbeperformedimmediately.PatientisstableIVlidocaine/procainamide/amiodarone.VTaimbeterminatedandPreventrecurrent.,Ventriculartachycardia,VENTRICULARARRHYTHMIAS-VT,SustainedVTDrugsAblationAICDSurgeon,VENTRICULARARRHYTHMIAS-VT,NonsustainedVT(NSVT)definedasrunsofthreeormorebeatslastinglessthan30seconds.ICDwillimproveprognosis.Betterprognosissuggeststhatbeta-blockersshouldbethefirstlineoftherapy.Althoughtherearenodefinitivedatawithamiodarone.Otherantiarrhythmicagentsshouldgenerallybeavoidedbecausctheirproarrhythmicriskappearstooutweighallybenefit,eveninpatientswithinduciblearrhythmiasthataresuccessfullysuppressedintheelectrophysiologylaboratory.,VENTRICULARFIBRILLATION,ThecausativerhythminmostCasesisventricularfibrillation,whichisusuallyprecededbyveutriculartachycardiaexceptinthesettingofacuteisehemiaorinfarction.Diagnosis:?!Treatment:Drugs/AICD!?,VentricularFlutterorfibrillation,ConductionDisturbance-Sicksin

温馨提示

  • 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
  • 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
  • 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
  • 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
  • 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
  • 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
  • 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

评论

0/150

提交评论